Evidence Table E3: DISCRETE outcomes for class RETINOID (TOPICAL).

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
	E.01.01			**Adapalene (0.03%)**	**Adapalene (0.1%)**	
338 ↑ Parallel Mild/mod/sev N=72		**Severe erythema**	Mid (12)	Present 0 Absent 24	Present 1 Absent 23	**NS**
	E.01.02			**Adapalene**	**Tretinoin**	
49 ↑ Parallel split face Mild/mod N=15		**Burning severity (patient)**	Short (2)	Very severe 0 Severe 0 Moderate 5 Slight 0 None 10	Very severe 0 Severe 4 Moderate 6 Slight 1 None 4	**0.02**
		Desquamation severity (invesigator)	Short (2)	Very severe 0 Severe 1 Moderate 5 Slight 7 None 2	Very severe 0 Severe 2 Moderate 6 Slight 5 None 2	**0.04**
		Edema severity (invesigator)	Short (2)	Very severe 0 Severe 0 Moderate 0 Slight 1 None 14	Very severe 0 Severe 0 Moderate 0 Slight 1 None 14	**NS**
		Erythema severity (invesigator)	Short (2)	Very severe 0 Severe 0 Moderate 1 Slight 8 None 6	Very severe 0 Severe 0 Moderate 5 Slight 6 None 4	**NS**
		Papules severity (invesigator)	Short (2)	Very severe 0 Severe 1 Moderate 7 Slight 6 None 1	Very severe 0 Severe 0 Moderate 7 Slight 7 None 1	**NS**

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
49 ↑ Parallel split face Mild/mod N=15		**Pruritis severity (patient)**	Short (2)	Very severe 0 Severe 0 Moderate 2 Slight 7 None 6	Very severe 0 Severe 0 Moderate 6 Slight 7 None 2	**0.02**
		Tightness severity (patient)	Short (2)	Very severe 0 Severe 1 Moderate 1 Slight 9 None 4	Very severe 0 Severe 1 Moderate 6 Slight 5 None 3	**0.02**
		Vesicle severity (invesigator)	Short (2)	Very severe 0 Severe 0 Moderate 0 Slight 0 None 15	Very severe 0 Severe 0 Moderate 0 Slight 0 None 15	**NS**
63 ↑ Parallel Mod/sev N=591		**Adverse reations** Between P-value: compare of total number of reports	Mid (12)	Irritation, erythema, dermatitis 6 Dry skin 4 Skin discomfort, pruritis 6 Acne flare 3 Infection, herpes 0 Sunburn 0 total cutaneous 19	Irritation, erythema, dermatitis 12 Dry skin 13 Skin discomfort, pruritis 10 Acne flare 2 Infection, herpes 1 Sunburn 1 Total cutaneous 39	**0.05**
		Discontinuation due to side effects	Mid (12)	Acne flare 2 Irritation 2 Dry skin 0	Acne flare 1 Irritation 4 Dry skin 2	
80 Parallel N=268		**Burning**	Short (2)	Moderate 5 Severe 3 Other 129	Moderate 34 Severe 5 Other 95	**0.01**
		Dryness	Short (2)	Moderate 10 Severe 5 Other 119	Moderate 17 Severe 5 Other 112	
		Scaling	Short (2)	Moderate 17 Severe 5 Other 112	Moderate 26 Severe 11 Other 97	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
80 ↑ Parallel N=268		**Burning**	Mid (12)	Moderate 1 Severe 0 Other 133	Moderate 9 Severe 2 Other 123	**0.01**
		Dryness	Mid (12)	Moderate 4 Severe 3 Other 127	Moderate 16 Severe 4 Other 114	**0.05**
		Scaling	Mid (12)	Moderate 9 Severe 3 Other 122	Moderate 12 Severe 2 Other 115	**0.05**
93 ↑ Parallel split face Mild/mod N=100		**Inter-treatment preference**	Short (4)	Easier to apply 80 Quickest to apply 58 Best smell 78 Feels the best 77	Easier to apply 20 Quickest to apply 40 Best smell 22 Feels the best 24	**0.001**
				Feels less greasy 66 Prefer 68	Feels less greasy 37 Prefer 38	
		Intoleranncc	Short (4)	Intolerance 32	Intolerance 70	**0.001**
100 Parallel Mod N=297		**Comedones change (count)**	Short (4)	75% or greater improvement 14 Less than 75% improvement 97	75% or greater improvement 10 Less than 75% improvement 106	**NS**
		Comedones change (count)	Mid (12)	75% or greater improvement 36 Less than 75% improvement 75	75% or greater improvement 26 Less than 75% improvement 100	**NS**
		Dose regime altered	Mid (12)	Regime altered 25	Regime altered 20	
		Side effects Between P-value: for burning and puritis	Mid (12)	Discontinuation drug related 8 Discontinuation probably not drug related 4 Skin discomfort 16	Discontinuation drug related 4 Discontinuation probably not drug related 2 Skin discomfort 9	**0.05**
140 Parallel Mild/mod N=105		**Side effects**	Mid (12)	Erythema 6 Dryness 11 Scaling 8 Immediate burning 2	Erythema 16 Dryness 15 Scaling 19 Immediate burning 19	
				Persistent burning 3	Persistent burning 12	
		Withdrawal due to side effects	Mid (12)	Irritation 1	Irritation 3	
306 ↑ Parallel Mod N=288		**Severity change**	Mid (12)	Non-inflammatory lesions 31 Total lesions 29 Inflammatory lesions 32	Non-inflammatory lesions 18 Total lesions 18 Inflammatory lesions 32	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
	E.01.02			**Adapalene (0.03%)**	**Tretinoin**	
338 ↑ Parallel Mild/mod/sev N=72		**Severe erythema**	Mid (12)	Present 0 Absent 24	Present 1 Absent 23	**NS**
	E.01.02			**Adapalene (0.1%)**	**Tretinoin**	
338 ↑ Parallel Mild/mod/sev N=72		**Severe erythema**	Mid (12)	Present 1 Absent 23	Present 1 Absent 23	**NS**
	E.02.01			**Isotretinoin**	**Vehicle**	
54 ↑ Parallel N=313		**Erythema score**	Long (14	Grade 0 31 Grade 1 67 Grade 2 27 Grade 3 5 Grade 4 0	Grade 0 52 Grade 1 67 Grade 2 16 Grade 3 3 Grade 4 0	
		Peeling score	Long (14	Grade 0 38 Grade 1 69 Grade 2 20 Grade 3 3 Grade 4 0	Grade 0 67 Grade 1 58 Grade 2 12 Grade 3 1 Grade 4 0	
173 Parallel Mild/mod N=77		**Local reactions I**	Mid (12)	Scaling 7 Stinging 0 Itching 1 Peeling 4	Scaling 3 Stinging 2 Itching 0 Peeling 3	
		Local reactions II	Mid (12)	Erythema 10 Burning 4 soreness 4 Dryness 3 Roughness 0	Erythema 1 Burning 0 Soreness 0 Dryness 0 Roughness 1	
	E.02.01			**Isotretinoin (0.05%)**	**Vehicle**	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
202 Parallel Mild/mod N=82		**Side effects**	Mid (12)	Erythema (withdraw) 1	Erythema (withdraw) 0	**0.05**
	E.02.01			**Isotretinoin (0.1%)**	**Vehicle**	
202 Parallel Mild/mod N=82		**Side effects**	Mid (12)	Erythema (withdraw) 0	Erythema (withdraw) 0	**0.05**
	E.02.02			**Isotretinoin**	**Benzoyl peroxide**	
173 ↑ Parallel Mild/mod N=77		**Local reactions I**	Mid (12)	Scaling 7 Stinging 0 Itching 1 Peeling 4	Scaling 7 Stinging 1 Itching 3 Peeling 2	
				Erythema 10 Burning 4 soreness 4 Dryness 3	Erythema 10 Burning 3 Soreness 3 Dryness 5	
		Local reactions II	Mid (12)	Roughness 0	Roughness 1	
	E.02.03			**Isotretinoin (0.05%)**	**Isotretinoin (0.1%)**	
202 Parallel Mild/mod N=82		**Side effects**	Mid (12)	Erythema (withdraw) 1	Erythema (withdraw) 0	**0.05**
	E.02.04			**Isotretinoin**	**Tretinoin**	
90 ↑ Parallel Mod N=30		**Irritation**	Mid (12)	Present 7	Present 0	
		Stinging, erythema, desquamation	Mid (12)	Present 0	Present 10	
98 Parallel N=18		**Comedones change**	Mid (12)	75% or greater reduction 3 25-75% reduction 2 25% or less reduction 3	75% or greater reduction 3 25-75% reduction 1 25% or less reduction 4	**NS**

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
98 Parallel N=18		**Inflammatory change (%)**	Mid (12)	75% or greater reduction 3 25-75% reduction 3 25% or less reduction 2	75% or greater reduction 2 25-75% reduction 3 25% or less reduction 3	**NS**
		Total lesions change (%)	Mid (12)	75% or greater reduction 2 25-75% reduction 5 25% or less reduction 1	75% or greater reduction 2 25-75% reduction 4 25% or less reduction 2	**NS**
	E.03.01			**Motretinide**	**Vehicle**	
60 Parallel Mild/mod N=257		**Overall change/physician**	Mid (8)	Worse 2 No change 13 Insufficient 11 Moderate 27 Good 19 Excellent 3	Worse 8 No change 12 Insufficient 9 Moderate 21 Good 17 Excellent 2	**NS**
		Reduction in application due to side effects	Mid (8)	Reduced # application 10	Reduced # application 7	**NS**
		Side effects	Mid (8)	Pruritis 34 Burning 25 Erythema + desquamation 23 Desquamation to erythema 10 Erythema no desquamation. 19 No side effects 23 local irritation (withdraw) 0	Pruritis 26 Burning 23 Erythema + desquamation 16 Desquamation to erythema 12 Erythema no desquamation. 14 No side effects 30 Local irritation (withdraw) 0	**NS**
		Total lesions change	Mid (8)	-1 (worse) 6 0% 1 1-49% 23 50-74% 27 57-99% 18 100%(eradication) 2	-1(worse) 4 0% 4 1-49% 22 50--74% 23 57-99% 14 100 (eradication) 1	**NS**
61 ↓ Parallel N=19		**Local reactions**	Mid (8)	Desquamation without erythema 1 Desquamation with erythema 3 Burning 2 Pruritis 4	Desquamation without erythema 2 Desquamation with erythema 4 Burning 4 Pruritis 7	**NS**
	E.03.02			**Motretinide (bid)**	**Motretinide (qd)**	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
253 ↑ Parallel Mod/sev N=60		**Overall change/physician**	Mid (8)	Excellent 2 Good 6 Moderate 8 Insufficient 2	Excellent 1 Good 8 Moderate 6 Insuffient 2	**NS**
				Unchanged 1 Aggravated	Unchanged 1 Aggravated	
	E.03.03			**Motretinide**	**Tretinoin**	
59 ↑ Parallel Mild N=37		**Burning**	Mid (8)	Present 2 Withdraw 0	Present 9 Withdraw 2	**0.05**
		Erythema desquamation	Mid (8)	Present 7	Present 14	**0.05**
		Total lesions	Mid (8)	Complete 6	Complete 6	**NS**
60 Parallel Mild/mod N=257		**Overall change/physician**	Mid (8)	Worse 2 No change 13 Insufficient 11 Moderate 27	Worse 0 No change 3 Insufficient 9 Moderate 11	**NS**
				Good 19 Excellent 3	Good 34 Excellent 13	
		Reduction in application due to side effects	Mid (8)	Reduced # application 10	Reduced # application 43	**NS**
		Side effects	Mid (8)	Pruritis 34 Burning 25 Erythema + desquamation 23 Desquamation to erythema 10	Pruritis 62 Burning 69 Erythema + desquamation 76 Desquamation to erythema 0	**NS**
				Erythema no desquamation. 19 No side effects 23 local irritation (withdraw) 0	Erythema no desquamation. 6 No side effects 0 Local irritation (withdraw) 2	
		Total lesions change	Mid (8)	-1 (worse) 6 0% 1 1-49% 23 50-74% 27	-1 (worse) 0 0% 2 1-49% 12 50-74% 19	**NS**
				57-99% 18 100%(eradication) 2	57-99% 29 100% (eradication) 8	
	E.03.03			**Motretinide (bid)**	**Tretinoin**	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
253 ↑ Parallel Mod/sev N=60		**Overall change/physician**	Mid (8)	Excellent 2 Good 6 Moderate 8 Insufficient 2	Excellent 3 Good 9 Moderate 5 Insufficient 1	**NS**
				Unchanged 1 Aggravated	Unchanged Aggravated 1	
	E.03.03			**Motretinide (qd)**	**Tretinoin**	
253 ↑ Parallel Mod/sev N=60		**Overall change/physician**	Mid (8)	Excellent 1 Good 8 Moderate 6 Insuffient 2	Excellent 3 Good 9 Moderate 5 Insufficient 1	**NS**
				Unchanged 1 Aggravated	Unchanged Aggravated 1	
	E.04.01			**Retinyl beta-glucuronide**	**Vehicle**	
145 ↑ Parallel Mild/mod N=29		**Adverse reaction**	Long (18	Any 0	Any 0	
		Non-responders	Long (18	Non-responders 1	Non-responders 4	
	E.04.02			**Retinyl beta-glucuronide**	**Tretinoin**	
146 ↑ Parallel Mild/mod N=15		**Adverse reaction**	Long (28	Erythema, drying, peeling, cracking 0	Erythema, drying, peeling, cracking 5	
		Non-responders	Long (28	Non-responders 1	Non-responders 0	
	E.05.01			**Tretinoin**	**Polyoprepolymer-2**	
219 ↑ Parallel Mild/mod N=344		**Side effects**	Short (4)	Peeling 18 Burning 14 Erythema 14 Tightness 34	Peeling 6 Burning 7 Erythema 9 Tightness 20	**NS**
				Itching 16 Dryness 26	Itching 7 Dryness 7	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
219 ↑ Parallel Mild/mod N=344		**Overall change/physician**	Mid (12)	Excellent 25 Fair to good 60	Excellent 10 Fair to good 30	**NS**
		Side effects	Mid (12)	Peeling 9 Burning 8 Erythema 9 Tightness 24	Peeling 2 Burning 1 Erythema 2 Tightness 13	**NS**
				Itching 15 Dryness 18	Itching 4 Dryness 2	
	E.05.01			**Tretinoin**	**Vehicle**	
60 Parallel Mild/mod N=257		**Overall change/physician**	Mid (8)	Worse 0 No change 3 Insufficient 9 Moderate 11	Worse 8 No change 12 Insufficient 9 Moderate 21	**0.0005**
				Good 34 Excellent 13	Good 17 Excellent 2	
		Reduction in application due to side effects	Mid (8)	Reduced # application 43	Reduced # application 7	**0.0005**
		Side effects	Mid (8)	Pruritis 62 Burning 69 Erythema + desquamation 76 Desquamation to erythema 0	Pruritis 26 Burning 23 Erythema + desquamation 16 Desquamation to erythema 12	**0.005**
		Total lesions change	Mid (8)	Erythema no desquamation. 6 No side effects 0 local irritation (withdraw) 2 -1 (worse) 0 0% 2 1-49% 12 50-74% 19	Erythema no desquamation. 14 No side effects 30 Local irritation (withdraw) 0 -1(worse) 4 0% 4 1-49% 22 50--74% 23	**0.0005**
				57-99% 29 100% (eradication) 8	57-99% 14 100 (eradication) 1	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
270 ↓ Parallel N=61		**Comedones severity**	Mid (8)	Marked 12 Moderate 11 Slight 3 None 4	Marked 0 Moderate 2 Slight 17 None 8	
		Improvement in papules	Mid (8)	Worse 0 Marked 2 Moderate 12 Slight 7 None 5	Worse 0 Marked 0 Moderate 0 Slight 7 None 20	
		Improvement on pustules	Mid (8)	Worse 0 Marked 3 Moderate 4 Slight 12 None 5	Worse 0 Marked 0 Moderate 0 Slight 5 None 19	
		Overall change	Mid (8)	Worse 2 Excellent 8 Good 9 Fair 7 Poor 3	Worse 3 Excellent 0 Good 0 Fair 7 Poor 20	
	E.05.01			**Tretinoin (0.02%)**	**Vehicle**	
58 ↓ Parallel Sev N=256		**Side effects** Between P-value: with respect to placebo	Short (2)	Erythema/peeling 58	Erythema/peeling 31	**0.001**
		Side effects	Mid (8)	Erythema/peeling 14	Erythema/peeling 4	
	E.05.01			**Tretinoin (0.025%)**	**Vehicle**	
198 ↑ Parallel N=60		**Clinical assessment**	Mid (12)	Marked improvement 10 Improved 11 Slight improvement 1 No change 0	Marked improvement 0 Improved 0 Slight improvement 1 No change 17	
		Side effects	Mid (12)	Worse 0 Soreness, erythema, irritation (withdraw) 0 Soreness, erythema, irritation 7 None 15	Worse 1 Soreness, erythema, irritation (withdraw) 0 Soreness, erythema, irritation 0 None 20	
	E.05.01			**Tretinoin (0.05%)**	**Vehicle**	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
58 ↓ Parallel Sev N=256		**Side effects**	Short (2)	Erythema/peeling 70	Erythema/peeling 31	**0.001**
		Side effects	Mid (8)	Erythema/peeling 16	Erythema/peeling 4	
198 ↑ Parallel N=60		**Clinical assessment**	Mid (12)	Marked improvement 3 Improved 11 Slight improvement 3 No change 0 Worse 0	Marked improvement 0 Improved 0 Slight improvement 1 No change 17 Worse 1	
		Side effects	Mid (12)	Soreness, erythema, irritation (withdraw) 1 Soreness, erythema, irritation 10 None 6	Soreness, erythema, irritation (withdraw) 0 Soreness, erythema, irritation 0 None 20	
	E.05.01			**Tretinoin (ethanol)**	**Vehicle**	
220 Parallel Mild/mod N=215		**Adverse effect**	Short (4)	Itching 9 Tightness 15 Burning 10 Erythema 28 Peeling 26 Dryness 19	Itching 4 Tightness 10 Burning 3 Erythema 13 Peeling 4 Dryness 8	
		Any adverse outcome	Short (4)	Skin/appendage adverse reaction 13	Skin/appendage adverse reaction 2	
		Adverse effects	Mid (12)	Itching 7 Tightness 9 Burning 7 Erythema 15 Peeling 15 Dryness 15	Itching 0 Tightness 6 Burning 1 Erythema 5 Peeling 2 Dryness 5	
		Dry skin Between P-value: .05 vs.tretinoin (polyolprepolymer-2), .05 vs. vehicle	Mid (12)	Present 6	Present 0	
		Eruption	Mid (12)	Present 9	Present 2	**NS**
		Other skin symptoms	Mid (12)	Severe (withdraw) 2 Stinging 1	Severe (withdraw) 0 Stinging 0	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
220 Parallel Mild/mod N=215		**Systemic adverse effects**	Mid (12)	Any adverse event 29	Any adverse event 25	**NS**
	E.05.01			**Tretinoin (polyoprepolymer-2)**	**Vehicle**	
220 Parallel Mild/mod N=215		**Adverse effect**	Short (4)	Itching 11 Tightness 13 Burning 6 Erythema 16	Itching 4 Tightness 10 Burning 3 Erythema 13	
				Peeling 12 Dryness 10	Peeling 4 Dryness 8	
		Any adverse outcome	Short (4)	Skin/appendage adverse reaction 11	Skin/appendage adverse reaction 2	
		Adverse effects	Mid (12)	Itching 4 Tightness 6 Burning 3 Erythema 7	Itching 0 Tightness 6 Burning 1 Erythema 5	
				Peeling 5 Dryness 6	Peeling 2 Dryness 5	
		Dry skin Between P-value: vs. tretinoin(ethanol)	Mid (12)	Present 1	Present 0	**0.05**
		Eruption	Mid (12)	Present 8	Present 2	**NS**
		Other skin symptoms	Mid (12)	Severe (withdraw) 0 Stinging 3	Severe (withdraw) 0 Stinging 0	
		Systemic adverse effects	Mid (12)	Any adverse event 30	Any adverse event 25	**NS**
	E.05.01			**Tretinoin + polyoprepolymer-2**	**Polyoprepolymer-2**	
219 ↑ Parallel Mild/mod N=344		**Side effects**	Short (4)	Peeling 26 Burning 20 Erythema 20 Tightness 40	Peeling 6 Burning 7 Erythema 9 Tightness 20	**NS**
				Itching 15 Dryness 26	Itching 7 Dryness 7	
		Overall change/physician	Mid (12)	Excellent 29 Fair to good 52	Excellent 10 Fair to good 30	**NS**

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
219 ↑ Parallel Mild/mod N=344		**Side effects**	Mid (12)	Peeling 10 Burning 8 Erythema 8 Tightness 18	Peeling 2 Burning 1 Erythema 2 Tightness 13	**NS**
				Itching 9 Dryness 15	Itching 4 Dryness 2	
	E.05.02			**Tretinoin**	**Benzoyl peroxide**	
38 ↓ Parallel Mod N=97		**Side effects**		Erythema and irritation 1 Slight stinging 1 Erythema and soreness 1	Soreness 1 Pruritis 1	
		Overall change/patient	Mid (12)	Improvement 35 No improvement 9	Improvement 14 No improvement 30	**0.001**
		Overall change/physician	Mid (12)	Improvement 38 No improvement 6	Improvement 19 No improvement 25	**0.001**
	E.05.02			**Tretinoin**	**Benzoyl peroxide (acetone)**	
221 ↓ Parallel Mod N=147		**Severity change**	Mid (8)	Excellent 15 Good 19 Fair 13 Poor 8	Excellent 20 Good 15 Fair 11 Poor 8	**NS**
	E.05.02			**Tretinoin**	**Benzoyl peroxide (alcohol)**	
221 ↓ Parallel Mod N=147		**Adverse reaction**	Mid (8)	Burning, erythema, peeling, severe 10 None 44	Burning, erythema, peeling, severe 20 None 18	
		Severity change	Mid (8)	Excellent 15 Good 19 Fair 13 Poor 8	Excellent 11 Good 8 Fair 11 Poor 8	**NS**
	E.05.04			**Tretinoin**	**Azelaic acid**	
188 ↑ Parallel N=289		**Erythema**	Long (24	Present 40 Absent 106	Present 25 Absent 118	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
188 ↑ Parallel N=289		**Overall change/physician**	Long (24	Excellent-good 60 Moderate 18 Poor 20	Excellent-good 58 Moderate 20 Poor 21	**NS**
		Scaling	Long (24	Present 42 Absent 104	Present 24 Absent 119	
	E.05.04			**Tretinoin + vehicle**	**Azelaic acid + glycolic acid**	
316 Parallel Mild N=70		**Side effects (patient assessment)** Between P-value: Dryness .001/Redness ..037/ Peeling .001	Mid (12)	Dryness 10 Redness 8 Peeling 5	Dryness 0 Redness 2 Peeling 0	
	E.05.07			**Tretinoin (0.02%)**	**Tretinoin (0.05%)**	
58 ↓ Parallel Sev N=256		**Side effects** Between P-value: with respect to placebo	Short (2)	Erythema/peeling 58	Erythema/peeling 70	**0.001**
		Side effects	Mid (8)	Erythema/peeling 14	Erythema/peeling 16	
	E.05.07			**Tretinoin (0.025%)**	**Tretinoin (0.05%)**	
198 ↑ Parallel N=60		**Clinical assessment**	Mid (12)	Marked improvement 10 Improved 11 Slight improvement 1 No change 0	Marked improvement 3 Improved 11 Slight improvement 3 No change 0	
		Side effects	Mid (12)	Worse 0 Soreness, erythema, irritation (withdraw) 0 Soreness, erythema, irritation 7 None 15	Worse 0 Soreness, erythema, irritation (withdraw) 1 Soreness, erythema, irritation 10 None 6	
	E.06.01			**Vitamin A**	**Vehicle**	
34 ↑ Parallel Mild/mod N=75		**Response**	Mid (12)	Poor 9 Fair 7 Good 14 Excellent 20	Poor 11 Fair 6 Good 4 Excellent 4	
		Side effects	Mid (12)	Erythema 47	Erythema & peeling 0	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
35 ↑ Parallel Mild/mod N=72		**Overall change**	Mid (12)	Excellent 10 Good 12 Fair 6 Poor 3	Excellent 5 Good 8 Fair 11 Poor 10	
		Overall change [female]	Mid (12)	Excellent 2 Good 7 Fair 1 Poor 1	Excellent 1 Good 5 Fair 3 Poor 3	**0.018**
		Overall change [male]	Mid (12)	Excellent 8 Good 5 Fair 5 Poor 2	Excellent 4 Good 3 Fair 8 Poor 7	**0.04**

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.